Order before 3pm, dispatched same day
Order before 3pm, dispatched same day Research Use Only
Pay by Card / Apple Pay
99% Purity Money Back Guarantee Retatrutide Now Available

Selank: Anxiolytic Peptide & Cognitive Research Overview

Back to library
peptide

Selank: Anxiolytic Peptide & Cognitive Research Overview

13 min read
Anxiolytic Research
Neuropeptide
Mechanism of Action
Last Updated: May 2026

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro; TKPRPGP) developed as a structural analog of tuftsin — a naturally occurring tetrapeptide with immunomodulatory and CNS activity — with an added Pro-Gly-Pro tripeptide at the C-terminus that substantially extends its metabolic stability. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences by the same research group responsible for Semax, Selank has accumulated a substantial published research record across anxiolytic pharmacology, GABA receptor modulation, enkephalinase inhibition, and immunomodulatory biology. Unlike classical anxiolytics (benzodiazepines, buspirone), Selank does not act primarily through direct GABA-A receptor agonism or benzodiazepine site binding — its mechanism is more complex and less well-characterised at the molecular level, which is part of what makes it an active area of neuropeptide research. Pure Grade Labs supplies research-grade Selank 10mg verified to ≥99% purity by HPLC with a batch-specific COA. Researchers studying the full spectrum of cognitive neuropeptide pharmacology may also wish to consider Semax, or the Cognitive Focus Research Stack combining both compounds.

Key Takeaways

  • Selank is a 7-amino acid synthetic peptide (TKPRPGP) — a structural analog of tuftsin (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro C-terminal extension. CAS: 129954-34-3. Molecular weight: 751.87 Da.
  • Primary research interest: anxiolytic activity without benzodiazepine-type sedation. Selank’s anxiolytic profile in rodent models is characterised by reduction in anxiety-related behaviour without the sedation, muscle relaxation, or dependence potential observed with classical benzodiazepine compounds.
  • Mechanism involves GABA system modulation and enkephalinase inhibition: Published studies indicate Selank modulates GABA-A receptor activity and inhibits enkephalin-degrading enzymes (enkephalinase), with downstream effects on endogenous opioid tone. The precise molecular target has not been fully elucidated.
  • Immunomodulatory effects in addition to CNS activity: Selank has demonstrated modulation of cytokine expression (IL-6, IL-1β, TNF-α) and immune cell function in published research, which is consistent with the immunomodulatory activity of its parent compound tuftsin.
  • Russian clinical research context: Selank has been approved in Russia as a tranquiliser for generalised anxiety disorder (GAD) and neurasthenia — providing a clinical literature base uncommon for synthetic peptide research compounds. For research purposes only outside Russia.
751.87 Da
Molecular weight of Selank (CAS: 129954-34-3) — heptapeptide TKPRPGP, synthetic tuftsin analog with Pro-Gly-Pro extension
GABA
Primary CNS system modulated by Selank — GABA-A receptor activity modulation without classical benzodiazepine-site direct agonism
Tuftsin
Parent peptide — Thr-Lys-Pro-Arg, naturally occurring C-terminal fragment of IgG with immunomodulatory and CNS activity
GAD
Generalised Anxiety Disorder — the primary clinical indication in Russian trials, where Selank is approved as a prescription anxiolytic tranquiliser

Research-Grade Selank — UK Supply

Selank 10mg. HPLC-verified ≥99% purity. Batch-specific COA included. For laboratory research purposes only.

View Selank 10mg →

What Is Selank? Structure and Origin

Selank (TKPRPGP) is a seven-amino-acid synthetic peptide constructed by extending the tuftsin tetrapeptide (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro tripeptide at the C-terminus. The parent compound, tuftsin, is a naturally occurring tetrapeptide that constitutes residues 289–292 of the Fc region of immunoglobulin G (IgG). Tuftsin was characterised by Victor Najjar at Tufts University in the 1970s and is produced in vivo by enzymatic cleavage of IgG; it has documented immunostimulatory effects (macrophage activation, phagocytosis promotion) and has been studied for CNS activity, particularly anxiolytic-like effects in rodent models.

The Pro-Gly-Pro extension added by researchers at the Institute of Molecular Genetics (IMGen), Russian Academy of Sciences — the same group responsible for Semax — addresses a key limitation of tuftsin: rapid metabolic degradation by prolyl endopeptidase and related serum enzymes. The C-terminal extension substantially extends the metabolic stability of the tuftsin core sequence, enabling systemic research administration in experimental models. This stabilisation is mechanistically identical to the approach used for Semax (MEHFPGP), where the same Pro-Gly-Pro extension extends the ACTH(4-7) sequence.

Selank was developed by Valentina Seredenin and colleagues at IMGen and registered as a pharmaceutical drug in Russia — initially as an anxiolytic for generalised anxiety disorder (GAD) and subsequently for neurasthenia and mild cognitive disorders. CAS number: 129954-34-3. Molecular formula: C33H57N9O9. Molecular weight: approximately 751.87 Da.

Mechanism of Action: How Selank Works

GABA System Modulation

The primary CNS mechanism attributed to Selank in the published literature involves modulation of the GABA-A receptor system. Unlike benzodiazepines, which act as positive allosteric modulators at a specific site on the GABA-A receptor complex, Selank does not appear to bind directly to the benzodiazepine site. Instead, published research suggests Selank modulates GABAergic neurotransmission through indirect mechanisms — the precise binding target has not been definitively established.

Seredenin SB et al. have published data demonstrating that Selank administration in rodent models produces anxiolytic-like effects that are partially reversed by the GABA-A antagonist flumazenil — implying involvement of the benzodiazepine binding site or an allosterically coupled site on the GABA-A receptor complex — but Selank’s binding characteristics differ from classical benzodiazepines in receptor binding assays. This mechanistic ambiguity is, from a research perspective, one of the compound’s most interesting properties: it may define a novel allosteric mechanism at GABA-A receptors.

Enkephalinase Inhibition

A second mechanistic contribution to Selank’s pharmacological profile involves inhibition of enkephalin-degrading enzymes — collectively referred to as enkephalinases, which include neprilysin (neutral endopeptidase 24.11) and dipeptidyl peptidase. Enkephalins are endogenous opioid pentapeptides (Met-enkephalin and Leu-enkephalin) that modulate pain, anxiety, and mood through mu and delta opioid receptors.

By inhibiting enkephalin degradation, Selank increases the effective concentration and duration of action of endogenous enkephalins in the CNS. This mechanism — increasing endogenous opioid tone without exogenous opioid administration — is similar in concept to the mechanism of racecadotril (enkephalinase inhibitor used in diarrhoea treatment) but with CNS rather than peripheral focus. The resulting increase in mu/delta receptor activation in limbic and frontal circuits is proposed as a contributing mechanism to Selank’s anxiolytic effects.

Serotonergic Modulation

Published neurochemical studies have found that Selank administration in rodent models is associated with increased serotonin (5-HT) turnover in limbic regions — the hippocampus and amygdala in particular. Serotonergic signalling in these regions is central to anxiety regulation, and this effect may explain part of the anxiolytic profile observed in behavioural models. The serotonergic effects are understood to be downstream of the primary GABA/enkephalin mechanisms rather than direct serotonin receptor binding.

In elevated plus-maze studies — the standard rodent anxiolytic assay — Selank-treated animals spent significantly more time in the open arms of the maze than vehicle controls, at a level comparable to the reference anxiolytic diazepam. The critical finding in Semenova and colleagues’ research was the absence of sedation or motor impairment at anxiolytic doses: open-field locomotor activity was not reduced, and the motor coordination measures (rotarod performance) were unaffected — a profile distinct from benzodiazepines. That mechanistic differentiation is precisely the research question that makes Selank an active area of GABA system investigation.

Anxiolytic Research: The Core Literature

The anxiolytic pharmacology of Selank is the most developed area of its published research record. Standard assays — elevated plus-maze (EPM), open-field test, Vogel conflict test, Geller-Seifter test — have consistently demonstrated anxiolytic-like effects in rodent models at doses in the range studied in the Russian research program.

Elevated Plus-Maze Studies

Multiple EPM studies in the Selank literature have demonstrated significant increases in open arm time and open arm entries in treated groups versus vehicle controls. The magnitude of the anxiolytic effect in EPM studies has been described as comparable to diazepam at reference doses, with the critical differentiator being absence of impaired motor coordination or sedation at anxiolytic doses. Semenova TP et al. and Seredenin SB et al. are the principal investigators in these studies, with research published across multiple decades of the compound’s development.

Conflict Test Models

Selank’s anxiolytic activity has also been confirmed in conflict-based assays (Vogel and Geller-Seifter), which are considered more robust indicators of anxiolytic efficacy than EPM because they require the animal to overcome conditioned fear in order to obtain reward. These assays are sensitive to classical anxiolytics (benzodiazepines, buspirone) and have shown positive responses to Selank, strengthening the construct validity of the anxiolytic classification.

Russian Clinical Research: GAD

Selank’s Russian pharmaceutical approval for generalised anxiety disorder (GAD) is based on clinical trials conducted in Russian research institutions. Published Russian-language and translated studies (Seredenin et al., Medvedev et al.) report significant improvements in Hamilton Anxiety Rating Scale (HAMA) scores in patients with GAD receiving Selank, compared to placebo. The magnitude of improvement has been reported as comparable to benzodiazepine reference comparators, with the safety profile showing no significant sedation, dependence signals, or withdrawal effects in the trial periods studied.

It is important to note that these trials were conducted in Russia under regulatory standards that differ from EMA or FDA requirements. They have not been replicated in Western regulatory-standard randomised controlled trials. Selank has no pharmaceutical marketing authorisation in the UK, EU, or USA, and is available outside Russia only as a research chemical.

Source Selank for Anxiolytic Research

Selank 10mg — HPLC ≥99% purity. Batch COA. UK supply. Also available: Semax 10mg and the Cognitive Focus Research Stack.

View Selank 10mg →

Cognitive Effects in Research Models

Beyond its anxiolytic profile, Selank has been studied in cognitive function models — an area where it overlaps with, but differs mechanistically from, Semax. The cognitive effects of Selank in published research appear to be secondary to its anxiolytic mechanism rather than a direct neurotrophin-mediated action of the kind characterised for Semax.

Semenova TP and colleagues have reported improvements in attention and working memory tasks in rodent models treated with Selank — effects attributed in part to reduced anxiety-induced impairment of cognitive performance (anxiolytic-mediated cognitive improvement) and in part to the serotonergic modulation observed in limbic regions. BDNF modulation has also been reported for Selank, though the magnitude and regional specificity differ from Semax’s BDNF effects.

In research terms, this raises the interesting question of whether Selank’s cognitive effects are primarily a consequence of anxiolysis (reducing the cognitive cost of anxiety in stressed models) or whether there is an independent direct cognitive mechanism. Separating these two contributions requires careful experimental design — a live research question in the neuropeptide literature.

Immunomodulatory Effects

The immunomodulatory properties of Selank are inherited from its parent compound tuftsin. Tuftsin is one of the most studied endogenous immunopeptides: it activates macrophages, natural killer cells, and neutrophils, and modulates cytokine production. Selank retains this immunomodulatory profile and has been studied specifically for effects on the expression of interleukins (IL-6, IL-1β) and tumour necrosis factor-alpha (TNF-α).

Uchakina ON et al. (2008) studied Selank’s effects on cytokine profiles in human subjects (a Russian clinical context), finding modulation of IL-6 and other cytokines. This immunomodulatory dimension is a distinct research interest from the anxiolytic and cognitive profiles — the compound has attracted research attention from immunologists as well as neuropharmacologists, making it one of the few synthetic peptides with documented activity across CNS and immune compartments simultaneously.

Selank vs. Semax: Research Profile Comparison

Dimension Selank Semax
Parent compound Tuftsin (immunopeptide) ACTH(4-7) (neuropeptide)
Primary mechanism GABA modulation, enkephalinase inhibition MC4R agonism, BDNF/NGF upregulation
Primary research area Anxiolytic pharmacology, GAD models Neuroprotection, cognitive function, stroke
BDNF modulation Reported — secondary mechanism Primary, well-characterised mechanism
Immunomodulation Documented — inherited from tuftsin Not a primary research focus
Russian approval indication Anxiolytic (GAD, neurasthenia) Neuroprotective (ischaemic stroke)
Molecular weight 751.87 Da 813.94 Da

Safety Profile

The Selank safety literature derives from Russian preclinical and clinical research. In rodent models, Selank demonstrates a favourable acute toxicology profile: LD50 values in mice are in a range consistent with low-toxicity classification, and no significant organ toxicity was observed in subacute rodent studies at doses multiples of those used in behavioural research protocols.

Critically, the Russian clinical trial literature has not identified the dependence liability, withdrawal syndrome, or motor impairment associated with benzodiazepine anxiolytics. This absence of dependence-related adverse effects has been a consistent finding across the Selank clinical literature and is the primary reason for ongoing research interest in its mechanism as a potential non-dependence-forming anxiolytic scaffold.

As with Semax, the safety literature for Selank meets Russian regulatory standards but has not undergone the full regulatory-standard evaluation required for pharmaceutical approval in the UK, EU, or USA. All research conducted with Selank outside Russia is under the research chemical framework.

Frequently Asked Questions

What is Selank used for in research?

In research contexts, Selank is used primarily as a tool compound for investigating anxiolytic mechanisms that differ from classical benzodiazepine pathways — specifically GABA-A receptor modulation via a novel allosteric mechanism, and enkephalinase inhibition. It is also studied for immunomodulatory effects (inherited from its tuftsin parent) and for cognitive function in anxiety-linked models.

How does Selank differ from benzodiazepines mechanistically?

Benzodiazepines are positive allosteric modulators that bind specifically to the benzodiazepine site on the GABA-A receptor and potentiate chloride ion influx. Selank modulates the GABA-A system through a mechanism that appears to involve the benzodiazepine-coupled allosteric system but does not involve direct classical benzodiazepine site binding. Selank also inhibits enkephalinase enzymes, increasing endogenous enkephalin tone — a mechanism not shared by benzodiazepines. This mechanistic differentiation is the subject of ongoing research into whether Selank represents a novel class of anxiolytic scaffold.

Is Selank approved in the UK?

Selank has no pharmaceutical marketing authorisation in the UK, EU, or USA. It is approved as a drug only in Russia, where it is available as a prescription nasal spray solution for generalised anxiety disorder and neurasthenia. Outside Russia, Selank is available strictly as a research chemical for laboratory research purposes only. It is not for human consumption in the UK.

What is tuftsin and how does it relate to Selank?

Tuftsin (Thr-Lys-Pro-Arg) is a naturally occurring tetrapeptide constituting residues 289–292 of the Fc region of IgG, produced in vivo by enzymatic cleavage. It has documented immunostimulatory activity (macrophage, NK cell, neutrophil activation) and has been studied for CNS effects including anxiolytic-like activity. Selank is a synthetic analog of tuftsin — the same TKPR sequence with a Pro-Gly-Pro C-terminal extension added to prevent rapid enzymatic degradation — retaining and extending the biological activity of the parent compound.

Can Selank and Semax be studied together?

Both Selank and Semax are supplied as research chemicals by Pure Grade Labs and are available individually or as the Cognitive Focus Research Stack. From a research design perspective, studying both compounds together versus separately allows mechanistic dissection of anxiolytic and neurotrophic pathways. Their distinct primary mechanisms (GABA/enkephalinase vs. MC4R/BDNF) make them useful complements in CNS neuropeptide research programmes, and some Russian research has examined both compounds in cognitive models for this reason.

Selank & Semax — UK Research Supply

Available individually or as the Cognitive Focus Research Stack. HPLC ≥99% purity. Batch COA. For research purposes only.

View Selank 10mg →

Summary

Selank (TKPRPGP) is a synthetic tuftsin analog with a documented anxiolytic research profile mediated through GABA-A system modulation and enkephalinase inhibition — a mechanism distinct from classical benzodiazepines and one that has attracted sustained research interest for its apparent absence of dependence liability and sedation in the published preclinical and clinical literature. Its immunomodulatory dimension, inherited from its tuftsin parent, adds a second research angle across CNS and immune biology.

The Russian clinical approval of Selank for generalised anxiety disorder provides a translational context unusual for synthetic peptide research compounds. While this does not equate to Western regulatory-standard clinical evidence, it represents a meaningful clinical research base — and the mechanistic questions it raises about non-benzodiazepine GABAergic anxiolysis remain active areas of neuropeptide research.

Pure Grade Labs supplies research-grade Selank 10mg verified to ≥99% purity by HPLC with a batch-specific COA. Researchers working across the full spectrum of cognitive neuropeptide pharmacology may also wish to consider Semax 10mg — whose BDNF/MC4R mechanism complements Selank’s GABA/enkephalinase profile — or the Cognitive Focus Research Stack combining both.

References

  1. Seredenin SB et al. (2008). Peptide selank activates the expression of genes involved in the regulation of the GABAergic and serotonergic systems in the brain. Doklady Biochemistry and Biophysics. 421:219-21.
  2. Semenova TP et al. (2009). Selank and short peptides of the tuftsin family in the regulation of adaptive behaviour in rats. Peptides. 30(6):1150-7.
  3. Uchakina ON et al. (2008). Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Eksperimental’naia i klinicheskaia farmakologiia. 71(4):23-6.
  4. Boyko SS et al. (2010). Pharmacokinetics of the novel peptide drug selank. Biomedical Chromatography. 24(10):1099-104. DOI: 10.1002/bmc.1414
  5. Najjar VA. (1987). Biological effects of tuftsin. Advances in Experimental Medicine and Biology. 208:11-23.
  6. Medvedev VE et al. (2015). Selank treatment for anxiety-asthenic disorders. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 115(6):33-40.
Disclaimer: This article is for research and informational purposes only. Selank is not approved as a pharmaceutical drug in the UK, EU, or USA. Research-grade Selank from Pure Grade Labs is sold for in vitro laboratory research purposes only and is not intended for human consumption or therapeutic use. This content does not constitute medical advice. Purchasers are responsible for compliance with all applicable regulations in their jurisdiction.